AR036176A1 - Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado - Google Patents
Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivadoInfo
- Publication number
- AR036176A1 AR036176A1 ARP020102690A ARP020102690A AR036176A1 AR 036176 A1 AR036176 A1 AR 036176A1 AR P020102690 A ARP020102690 A AR P020102690A AR P020102690 A ARP020102690 A AR P020102690A AR 036176 A1 AR036176 A1 AR 036176A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivative
- formula
- group
- preparation
- branched
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- MENMPXBUKLPJKR-UHFFFAOYSA-N 5-propan-2-yl-1,3-thiazol-2-amine Chemical compound CC(C)C1=CN=C(N)S1 MENMPXBUKLPJKR-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- -1 amino, aminomethyl Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- HJZGXXPOKWGQHH-UHFFFAOYSA-N n-(4-phenyl-1,3-thiazol-2-yl)acetamide Chemical class S1C(NC(=O)C)=NC(C=2C=CC=CC=2)=C1 HJZGXXPOKWGQHH-UHFFFAOYSA-N 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un derivado de fenil-acetamido-tiazol representado por la fórmula (1), donde: R es un átomo de hidrógeno o un grupo alquilo C1-4 recto o ramificado; R1 se selecciona del grupo de fórmulas (2) a (6) donde: R2 es hidrógeno o un grupo alquilo C1-6 recto o ramificado y el grupo hidroxi sobre el anillo de fórmula (4) se encuentra en cualquiera de las posiciones libres; R3 se selecciona entre el grupo que consiste en amino, aminometilo (-CH2-NH2), hidroximetilo (-CH2OH), alquilo C1-4 recto o ramificado, o es un heterociclo de 5 ó 6 miembros con 1 ó 2 heteroátomos seleccionados entre nitrógeno, oxígeno y azufre; siempre que, cuando R es hidrógeno, entonces R3 es diferente de metilo o piridil-3-ilo; o una sal farmacéuticamente aceptable del mismo. Su uso, un procedimiento para su preparación, una composición farmacéutica que lo comprende, un producto o kit que los comprende, y un método que utiliza el derivado de fórmula (1). El derivado de fórmula (1) es útil para el tratamiento de trastornos proliferativos celulares, por ejemplo, cáncer, asociados con una actividad de quinasa que depende de un ciclo celular alterado. Un procedimiento para la preparación de los compuestos de fórmula (1) o sus sales farmacéuticamente aceptables, que comprende la reacción de 2-amino-5-isopropil-1,3-tiazol con un compuesto de fórmula (7) donde R y R1 son los definidos en la reivindicación 11, y R' es hidroxi o un grupo de partida adecuado y, opcionalmente, convirtiéndolos en sus sales farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90794701A | 2001-07-19 | 2001-07-19 | |
| US35764202P | 2002-02-20 | 2002-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036176A1 true AR036176A1 (es) | 2004-08-18 |
Family
ID=26999733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102690A AR036176A1 (es) | 2001-07-19 | 2002-07-18 | Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20040235919A1 (es) |
| EP (1) | EP1406899B1 (es) |
| JP (1) | JP2004534857A (es) |
| KR (1) | KR100908794B1 (es) |
| CN (1) | CN1286835C (es) |
| AR (1) | AR036176A1 (es) |
| AT (1) | ATE345341T1 (es) |
| AU (1) | AU2002325860B2 (es) |
| BR (1) | BR0211265A (es) |
| CA (1) | CA2453294A1 (es) |
| CY (1) | CY1105948T1 (es) |
| CZ (1) | CZ2004107A3 (es) |
| DE (1) | DE60216097T2 (es) |
| DK (1) | DK1406899T3 (es) |
| EA (1) | EA007392B1 (es) |
| ES (1) | ES2274076T3 (es) |
| GE (1) | GEP20105095B (es) |
| IL (2) | IL159570A0 (es) |
| MX (1) | MXPA04000407A (es) |
| NO (1) | NO20040210L (es) |
| NZ (1) | NZ530524A (es) |
| PL (1) | PL367938A1 (es) |
| PT (1) | PT1406899E (es) |
| WO (1) | WO2003008365A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| RU2383542C2 (ru) * | 2004-08-17 | 2010-03-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные гидантоины |
| US7550598B2 (en) | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| TW200621766A (en) * | 2004-09-17 | 2006-07-01 | Hoffmann La Roche | Substituted hydantoins |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| BRPI0719883A2 (pt) | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Inibidores de quinase |
| US8168794B2 (en) | 2008-03-03 | 2012-05-01 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| EA026432B1 (ru) | 2012-05-21 | 2017-04-28 | Новартис Аг | Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ |
| EP2925750A1 (en) | 2012-11-29 | 2015-10-07 | Karyopharm Therapeutics, Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| AU2014285019C1 (en) | 2013-07-03 | 2019-05-02 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof |
| WO2015042414A1 (en) * | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| MX2018001979A (es) | 2015-08-18 | 2019-04-25 | Karyopharm Therapeutics Inc | (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer. |
| WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| SG11202100531RA (en) | 2018-09-17 | 2021-02-25 | Yungjin Pharm Co Ltd | Novel thiazole derivatives and pharmaceutically acceptable salts thereof |
| KR102335637B1 (ko) * | 2020-03-13 | 2021-12-06 | 영진약품 주식회사 | 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염 |
| CN112979634A (zh) * | 2021-02-06 | 2021-06-18 | 绍兴文理学院 | 一种含酰胺结构的噻唑类化合物及其制备方法和应用 |
| CN112979636A (zh) * | 2021-02-06 | 2021-06-18 | 绍兴文理学院 | 一种含苯硫醚结构的噻唑类化合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6214852B1 (en) * | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
-
2002
- 2002-07-02 PL PL02367938A patent/PL367938A1/xx not_active Application Discontinuation
- 2002-07-02 DK DK02760213T patent/DK1406899T3/da active
- 2002-07-02 WO PCT/EP2002/007289 patent/WO2003008365A2/en not_active Ceased
- 2002-07-02 BR BR0211265-5A patent/BR0211265A/pt not_active IP Right Cessation
- 2002-07-02 CZ CZ2004107A patent/CZ2004107A3/cs unknown
- 2002-07-02 CN CNB028143388A patent/CN1286835C/zh not_active Expired - Fee Related
- 2002-07-02 ES ES02760213T patent/ES2274076T3/es not_active Expired - Lifetime
- 2002-07-02 GE GEAP200911511A patent/GEP20105095B/en unknown
- 2002-07-02 AT AT02760213T patent/ATE345341T1/de not_active IP Right Cessation
- 2002-07-02 EP EP02760213A patent/EP1406899B1/en not_active Expired - Lifetime
- 2002-07-02 EA EA200400208A patent/EA007392B1/ru not_active IP Right Cessation
- 2002-07-02 DE DE60216097T patent/DE60216097T2/de not_active Expired - Lifetime
- 2002-07-02 IL IL15957002A patent/IL159570A0/xx not_active IP Right Cessation
- 2002-07-02 US US10/483,620 patent/US20040235919A1/en not_active Abandoned
- 2002-07-02 MX MXPA04000407A patent/MXPA04000407A/es active IP Right Grant
- 2002-07-02 PT PT02760213T patent/PT1406899E/pt unknown
- 2002-07-02 AU AU2002325860A patent/AU2002325860B2/en not_active Ceased
- 2002-07-02 NZ NZ530524A patent/NZ530524A/en not_active IP Right Cessation
- 2002-07-02 KR KR1020047000859A patent/KR100908794B1/ko not_active Expired - Fee Related
- 2002-07-02 JP JP2003513926A patent/JP2004534857A/ja not_active Ceased
- 2002-07-02 CA CA002453294A patent/CA2453294A1/en not_active Abandoned
- 2002-07-18 AR ARP020102690A patent/AR036176A1/es unknown
-
2004
- 2004-01-16 NO NO20040210A patent/NO20040210L/no not_active Application Discontinuation
-
2007
- 2007-01-25 CY CY20071100090T patent/CY1105948T1/el unknown
-
2010
- 2010-04-08 IL IL204947A patent/IL204947A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1406899E (pt) | 2007-01-31 |
| NZ530524A (en) | 2006-12-22 |
| CA2453294A1 (en) | 2003-01-30 |
| GEP20105095B (en) | 2010-10-25 |
| HK1068336A1 (en) | 2005-04-29 |
| WO2003008365A3 (en) | 2004-02-12 |
| PL367938A1 (en) | 2005-03-07 |
| EP1406899B1 (en) | 2006-11-15 |
| AU2002325860B2 (en) | 2008-03-13 |
| CZ2004107A3 (cs) | 2004-04-14 |
| IL159570A0 (en) | 2004-06-01 |
| BR0211265A (pt) | 2004-07-20 |
| CY1105948T1 (el) | 2011-04-06 |
| JP2004534857A (ja) | 2004-11-18 |
| DE60216097T2 (de) | 2007-06-28 |
| DE60216097D1 (de) | 2006-12-28 |
| CN1286835C (zh) | 2006-11-29 |
| MXPA04000407A (es) | 2004-03-18 |
| KR20040030821A (ko) | 2004-04-09 |
| IL204947A0 (en) | 2010-11-30 |
| EA200400208A1 (ru) | 2004-06-24 |
| NO20040210L (no) | 2004-03-03 |
| ATE345341T1 (de) | 2006-12-15 |
| EP1406899A2 (en) | 2004-04-14 |
| US20040235919A1 (en) | 2004-11-25 |
| DK1406899T3 (da) | 2007-04-02 |
| CN1531535A (zh) | 2004-09-22 |
| WO2003008365A2 (en) | 2003-01-30 |
| EA007392B1 (ru) | 2006-10-27 |
| KR100908794B1 (ko) | 2009-07-22 |
| ES2274076T3 (es) | 2007-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036176A1 (es) | Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado | |
| AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
| DK633088D0 (da) | Hidtil ukendte forbindelser | |
| PE20030601A1 (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados | |
| BR0008770A (pt) | Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| AR007828A1 (es) | Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos | |
| DK0687253T3 (da) | Hidtil ukendte 4-aminopyridiner, fremgangsmåde til deres fremstilling samt lægemidler indeholdende disse forbindelser | |
| ES2054309T3 (es) | Compuestos de urea sustituida y su preparacion y uso. | |
| DK0649418T3 (da) | 7-(2-aminoethyl)benzothiazolon | |
| AR042547A1 (es) | Uso de acidos alfa - feniltiocaboxilico y alfa - feniloxicarboxilico con actividad disminuidora de la glucosa en el suero y de los lipidos en el suero | |
| ATE244221T1 (de) | Pyrrolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| EP1227085A4 (en) | PROCESS FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE DERIVATIVE AND ITS OPTICAL SEPARATOR | |
| DOP2001000190A (es) | Nuevo procedimiento para la preparación de las pirazolopirimidinonas | |
| UY27324A1 (es) | Nuevas sales de napsilato i | |
| ES8601209A1 (es) | Procedimiento para preparar derivados de 5h-(1)-benzopirano-(2,3-d)pirimidina | |
| AR036056A1 (es) | Formulaciones de lactonas y metodos de uso de las mismas | |
| EA200100725A2 (ru) | Новые бензотиадиазиновые соединения, способ их получения и их содержащие фармацевтические композиции | |
| AR046212A1 (es) | Derivados de 2-fenilbenzofurano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| ES2070959T3 (es) | Utilizacion de derivados del bis(4-hidroxifeniltio)metano en el tratamiento de la diabetes mellitus. | |
| EA200200379A2 (ru) | Новые соединения пиримидин-4-она, способ их получения и содержащие их фармацевтические композиции | |
| CO5650239A2 (es) | Derivados de acido 2-etoxi-3-fenilpropionico para el tratamiento de trastornos de lipidos | |
| AR044477A1 (es) | Derivados de anilina, composiciones farmaceuticas que las contienen y procedimiento para su preparacion | |
| ECSP034536A (es) | Derivados de acido propionico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |